

Please type a plus sign (+) inside the

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Application Number 10/644,592  
Filing Date August 19, 2003  
First Named Inventor Miculka et al.  
Group Art Unit 1623  
Examiner Name Not yet assigned  
Attorney Docket Number 612,406-035

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<del>XX</del>	AA	5,885,070 A		Wels	03/1998	
<del>XX</del>	AB	5,874,553 A		Peyman	02/1999	
<del>XX</del>	AC	5,849,482 A		Meyer, Jr.	12/1998	
<del>XX</del>	AD	5,788,607 A		Goodnow	07/1998	
<del>XX</del>	AE	5,808,940 A		Wirth	03/1997	
<del>XX</del>	AF	5,803,262 A		Wirth	03/1997	
<del>XX</del>	AG	5,550,223 A		Wirth	09/1996	
<del>XX</del>	AH	5,349,203 A		Hanazato et al.	09/1994	
<del>XX</del>	AI	5,342,692 A		Ribi	08/1994	
<del>XX</del>	AJ	5,087,952 A		Ribi	02/1992	
<del>XX</del>	AK	4,952,588 A		Sekimaki	08/1990	
<del>XX</del>	AL	4,948,950 A		Bubek	04/1990	
<del>XX</del>	AM	4,885,211 A		Tang et al.	12/1989	
<del>XX</del>	AN	4,777,019 A		Dandekar	10/1988	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<del>XX</del>	AO	DE	3513168	A1		10/1986		
<del>XX</del>	AP	DE	10744716	A1		09/1997		
<del>XX</del>	AQ	EP	0491059	A1		10/1993		
<del>XX</del>	AR	EP	0739898	A2		10/1996		
<del>XX</del>	AS	GB	2266182	A		10/1993		
<del>XX</del>	AT	JP	57 146706			03/1983		
<del>XX</del>	BA	JP	10 306907	A		11/1988		
<del>XX</del>	BB	WO	94/20589	A2		09/1994		
<del>XX</del>	BC	WO	95/21184	A2		08/1995		
<del>XX</del>	BD	WO	96/12728	A1		05/1996		
<del>XX</del>	BE	WO	96/39414	A1		12/1996		
<del>XX</del>	BF	WO	97/00882	A1		01/1997		
<del>XX</del>	BG	WO	98/25943			06/1998		
<del>XX</del>	BH	WO	98/56761	A2		12/1998		
<del>XX</del>	BI	WO	99/45530	A3		04/1999		
<del>XX</del>	BJ	WO	01/13126	A1		02/2001		

Examiner Signature

L. E. Crane

Date Considered

10/24/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IR1:1057571.1

\*\* Duplicate citation: see PTO-892 for original citation.

10/644,592 - PTO-1449 #1

COPY: FOR ~~File~~

[X] Applicant

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/644,592
		Filing Date	August 19, 2003
		First Named Inventor	Miculka et al.
		Group Art Unit	1623
		Examiner Name	Not yet assigned
Sheet	2	of	4
		Attorney Docket Number	612,406-035

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>MC</i>	BK	ADACHI, Chihaya, et al. "Durability Characteristics of Aminopyrene Dimer Molecules as an Emitter in Organic Multilayered Electroluminescent Diodes." Jpn. J. Appl. Phys. 35: 4819-25 (Sep., 1996).	
<del>MC</del>	<del>BL</del>	<del>BOLLICH et al., "434. Pyranosyl-RNA: Further Observations on Replication," Helvetica Chimica Acta, 80(6), 1901-1951 (Sep. 22, 1998).", Helvetica Chimica Acta, 80</del>	
<del>MC</del>	<del>BM</del>	<del>DeClercq et al. "Effects of 5-5 (2-bromovinyl)-2'-deoxyuridine and Other Selective Antihelminth Compounds on the Induction of Retroviral Particles in Mouse BALB-3T3 Cells," Molecular Pharmacology, 19(1), 122-129 (1981);, Chem. Abstracts, 94(17), p. 38, Abstr. No. 132,049y (Apr. 27, 1981).", Molecular Pharmacology Chem. Abstracts</del>	
<del>MC</del>	<del>BN</del>	<del>DOBOSZEWSKI et al., "Synthesis of 3'-Deoxy-3'-C-Hydroxymethyl-aldopyranosyl Nucleosides and their Incorporation in Oligonucleotides. Part II," Tetrahedron, 51(45), 12319-12338 (1995).", Tetrahedron, 51</del>	
<i>MC</i>	BO	DOBOSZEWSKI, B., et al. "3'-Deoxy-3'-Hydroxymethyl-aldopentopyranosyl Nucleoside Synthesis. Part I." Tetrahedron 51(18): 5381-96 (1995).	
<del>MC</del>	<del>BP</del>	<del>DOUKI et al., "Measurement of Pyrimidine (B-A) Photoproducts in DNA by a Mild Acidic Hydrolysis-HPLC Fluorescence Detection Assay," Chemical Research in Toxicology, 8(2), 244-253 (Mar. 1995).", Chemical Research in Toxicology, 8</del>	
<del>MC</del>	<del>BQ</del>	<del>GIBSON et al., "Synthesis and Application of Derivatizable Oligonucleotides," Nucleic Acids Research, 15(16), 6455-6467 (Aug. 25, 1987);, Chem. Abstracts, 108(9), pp. 340-341, Abstr. No. 71626t (Feb. 29, 1988).", Nucleic Acids Research Chem. Abstracts</del>	
<del>MC</del>	<del>BR</del>	<del>KELLEY et al., "Furanose-Pyranose Isomerization of Reduced Pyrimidine and Cyclic Urea Ribosides," Journal of Medicinal Chemistry, 29(11), 2351-2358 (Nov. 1986).", Journal of Medicinal Chemistry, 29</del>	
<del>MC</del>	<del>BS</del>	<del>MELQUIZ et al., "A New One-Step Synthesis of 8-Deoxy Nucleoside Analogues from 6-(Glucosylamino)-5-nitropyrimidines," Journal of Organic Chemistry, 57(2), 559-565 (Jan. 17, 1992).", Journal of Organic Chemistry, 57</del>	
<del>MC</del>	<del>BT</del>	<del>PIESCH et al. (I), "147. Why Pentose and Not Hexose Nucleic Acids? Pyranosyl RNA (p-RNA)," Helvetica Chimica Acta, 76(6), 2181-2183 (1993).", Helvetica Chimica Acta, 76</del>	
<del>MC</del>	<del>BU</del>	<del>PIESCH et al. (II), "132. Pyranosyl RNA (p-RNA): Base Pairing Selectivity and Potential to Replicate," Helvetica Chimica Acta, 78(8), 1621-1635 (1995).", Helvetica Chimica Acta, 78</del>	
<del>MC</del>	<del>BV</del>	<del>SCHLONDOGT et al., "188. Pyranosyl RNA (p-RNA): NMR and Molecular Dynamics Study of the Duplex Formed by Self-pairing of Ribopyranosyl-(C-G-A-A-T-T-C-G)," Helvetica Chimica Acta, 79(8), 2318-2345 (Dec. 11, 1996).", Helvetica Chimica Acta, 79</del>	

Examiner Signature	L. E. Crane <i>L. E. Crane</i>	Date Considered	10/24/2005
--------------------	--------------------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

\*\* Duplicate citation: see PTO-892 for original citation.

IRI:1057571.1

10/644,592 - PTO-1449 #1

COPY FOR *File*

*[10]* Applicant

Please type a plus sign (+) inside this box →




PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/644,592
		Filing Date	August 19, 2003
		First Named Inventor	Miculka et al.
		Group Art Unit	1623
		Examiner Name	Not yet assigned
		Attorney Docket Number	612,406-035
Sheet	3	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JEC	BW	ADAMS, David R., et al. "Preparation and Anti-HIV activity of N-3- Substituted Thymidine Nucleoside Analogs." J. Med. Chem. 40: 1550-58 (1997); Abstract published Apr. 1, 1997.	
	BX	CADET, J. <i>Tetrahedron Letters</i> 11: 867-70 (1974).	
	BY	EDWARDS, Christine, et al. "Synthesis of 2-substituted 2'-deoxyguanosines and 6-O-allylguanines via activation C-2 by a trifluoromethanesulfonate group." J. Chem. Soc., Perkins Trans. 1: 1887-93 (1997).	
	BZ	GIBSON, Katherine J., et al. "Synthesis and application of derivatizable oligonucleotides." <i>Nucleic Acids Research</i> 15(16): 6455-67 (1987); Aug. 25, 1987.	
	CA	GUPTA, Vineet et al. "A Self-Cleaving DNA Nucleoside." <i>Chem. Commun.</i> 1425- 26 (1997).	
	CB	HOSSAIN, Nafizal, et al. "Synthesis and Antiviral Activity of the [agr]- Analogues of 1,5-Anhydroxitol Nucleosides (1,5-Anhydro-2,3-dideoxy-D- ribohaxitol Nucleosides)." J. Org. Chem.. 62: 2442-47 (1997); Abstract published Mar. 15, 1997.	
	CC	IYER, Radhakrishnan P., et al. "N-pent-4-enoyl (PNT) Group as a Universal Nucleobase Protector: Applications in the Rapid and Facile Synthesis of Oligonucleotides, Analogs, and Conjugates." <i>Tetrahedron</i> 53(8): 2731-50 (1997).	
	CD	KERN, D.L., et al. "9-[bgr]-D-Ribopyranosylhypoxanthine, A Minor Component Produced by <i>Streptomyces Antibioticus</i> ." J. Heterocyclic Chem. 17:461-63 (1980); May, 1980.	
	CE	NAGATSUGI, F., et al. "2-Aminopurine Derivatives with C8-Substituted Cisin as Novel Cross-linking Agents and the Synthesis of the Corresponding [bgr]-Phosphoramidite Precursors." <i>Tetrahedron</i> 53(9): 3035-44 (1997).	
	CF	NODA, Tetsuya, et al. "A novel yellow-emitting material, 5,5'-bis(4- methylphenyl) amino phenyl)-2-2':5'-terthiophene, for organic electroluminescent devices. <i>Appl. Phys. Lett.</i> 70(6): 699-701 (1997); Feb. 10, 1997.	
	CG	TAYLOR, M., et al. "Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." <i>J. Med. Chem.</i> 29:346-53 (1986).	
	CH	TORRENCE, Pail F., et al. "5-O-Alkylated Derivatives of 5-Hydroxy-2'- deoxyuridine as Potential Antiviral Agents: Anti-Herpes Activity of 5- Propynyloxy-2'-deoxyuridine." <i>J. Med. Chem.</i> 21(2):228-31 (1978).	
Re	CI	XIA, Xiaoyang, et al. "Stereo-controlled Synthesis of [bgr]-2'- deoxyprimidine Nucleosides via Intramolecular Glycosylations." <i>Tetrahedron Letters</i> 38(7): 1111-14 (1997).	

Examiner Signature	L. E. Crane 	Date Considered	10/24/2005
--------------------	---	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IRI:1057571.1

10/644,592 - PTO-1449 #1

COPY FOR



☒ Applicant

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/644,592
		Filing Date	August 19, 2003
		First Named Inventor	Miculka et al.
		Group Art Unit	1623
		Examiner Name	Not yet assigned
		Attorney Docket Number	612,406-035
Sheet	4	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JEC	CJ	HANAZATO, Yoshio, et al. "Integrated Multi-Biosensors Based on an Ion-Sensitive Field-Effect Transistor Using Photolithographic Techniques." IEEE Transactions on Electron Devices 36(7): 1303-09 (1989); Jul., 1989.	
	CK	HOLY, A. "Preparation of Acyl Derivatives of Pyrimidin-2-one Nucleosides by the Silyl Variant of the Hilbert-Johnson Reaction." Collection Czechoslov. Chem. Commun. 42: 902-08 (1977).	
JEC	CL	LEWIS, A., et al. "Derivatives of the Nucleoside Antibiotics, Toyocamycin and Sangivamycin, Analogs of N6-((Dgr)2-Isopentenyl)adenosine." J. Heterocyclic Chem. 11:71-72 (1974); Feb., 1974.	
	CM	WATANABE, K.A., et al. "Nucleosides. LXXXVII. Total Synthesis of Pentopyranine A, an [agr]-L Cytosine Nucleoside Elaborated by Streptomyces griseochromogenes." J. Org. Chem. 39(17):2482-88 (1974).	
	CN		
	CO		
	CP		
	CQ		
	CR		
	CS		
	CT		
	CU		
	CV		
	CW		

Examiner Signature	L. E. Crane	Date Considered	10/24/2005
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IRI:1057571.1